Related Experiment Video

Updated: Apr 30, 2026

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

11.1K

BET Inhibitor JQ1 Blocks Inflammation and Bone Destruction

S Meng1, L Zhang1, Y Tang1

  • 1Division of Oral Biology, Tufts University School of Dental Medicine, Boston, MA 02111, USA State Key Laboratory of Oral Diseases, West China School of Stomatology, Sichuan University, Chengdu 610041, China.

Journal of Dental Research
|May 7, 2014
PubMed

Insights

The BET inhibitor JQ1 effectively reduces inflammation and bone loss in experimental periodontitis. By targeting epigenetic regulators, JQ1 suppresses key inflammatory pathways and osteoclast formation, offering a potential new treatment for this destructive disease.

Area of Science:

  • Epigenetics
  • Pharmacology
  • Periodontology

Background:

  • BET proteins are epigenetic regulators crucial for transcription.
  • Dysregulation of BET proteins is implicated in various diseases.
  • JQ1 is a novel BET inhibitor with known anti-inflammatory and anti-oncogenic properties.

Purpose of the Study:

  • To investigate the therapeutic potential of JQ1 in experimental periodontitis.
  • To elucidate the molecular mechanisms underlying JQ1's effects on inflammation and bone destruction.

Main Methods:

  • In vitro studies using LPS-stimulated cells to assess cytokine and osteoclast marker expression.
  • In vivo studies using a murine periodontitis model to evaluate JQ1's systemic effects.
  • Chromatin immunoprecipitation and quantitative polymerase chain reaction (ChIP-qPCR) to analyze BRD4 binding.

Main Results:

  • JQ1 suppressed key inflammatory cytokines (IL-1β, IL-6, TNF-α) and osteoclast markers in vitro.
  • JQ1 inhibited TLR2/4 expression and NF-κB signaling pathway activation.
  • JQ1 treatment reduced inflammatory cytokine expression and alveolar bone loss in a murine periodontitis model by decreasing osteoclast activity.
  • JQ1 was shown to neutralize BRD4 enrichment at critical gene promoter regions.

Conclusions:

  • JQ1 demonstrates significant efficacy in mitigating inflammation and bone destruction associated with periodontitis.
  • JQ1's mechanism involves the suppression of inflammatory gene transcription and osteoclastogenesis via BRD4 inhibition.
  • JQ1 represents a promising novel therapeutic candidate for periodontitis treatment.
Keywords:
BRD4 proteinanti-inflammatory agentsepigeneticsexperimental animal modelsosteoclastsperiodontitis

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
106
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
12.5K
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
8.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.2K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755